SCHEMBL18539736

SCHEMBL18539736

CCOCc1nc(-c2ccccc2)ncc1NC(=O)OC(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
MAPT P10636 2/20 0.41
LMNA P02545 2/20 0.41
MAPK1 P28482 1/20 0.41
ATM Q13315 1/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
TP53 P04637 1/20 0.41
HPGDS O60760 1/20 0.40
CNR2 P34972 1/20 0.40
BRD9 Q9H8M2 1/20 0.40
CKS1B P61024 3/20 0.39
SKP1 P63208 3/20 0.39
SKP2 Q13309 3/20 0.39
MAPKAPK2 P49137 1/20 0.39
CYP1A2 P05177 1/20 0.39
POLB P06746 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18549729 0.89 RXFP1 (0.39) ALDH1A1LMNANPC1RAB9AHPGDS
SCHEMBL18549873 0.86 LMNA (0.40) LMNANPC1RAB9AHPGDSCNR2
SCHEMBL18539733 0.85 NTRK1 (0.37) LMNANPC1RAB9AHPGDSCNR2
SCHEMBL18539738 0.80 NTRK1 (0.46) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL18539734 0.75 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2MAPTLMNAMAPK1
SCHEMBL18660852 0.75 SCN9A (0.41) ALDH1A1SMN1; SMN2MAPTLMNAMAPK1
SCHEMBL6879938 0.74 ALDH1A1 (0.54) ALDH1A1SMN1; SMN2MAPTLMNANPC1
SCHEMBL18660859 0.72 SCN9A (0.40) ALDH1A1SMN1; SMN2MAPTLMNAMAPK1
SCHEMBL18539732 0.72 ALDH1A1 (0.69) ALDH1A1SMN1; SMN2MAPTLMNAMAPK1
SCHEMBL18539731 0.72 HTT (0.37) ALDH1A1LMNATP53MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170050934-A1 ETHERIC (ETHEREAL) OXYGEN ATOM-CONTAINING PERFLUOROALKYL GROUP-SUBSTITUTED PYRIMIDINE RING COMPOUND, AND METHOD FOR ITS PRODUCTION ASAHI GLASS COMPANY, LIMITED (JP) 2017-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170050934-A1 ETHERIC (ETHEREAL) OXYGEN ATOM-CONTAINING PERFLUOROALKYL GROUP-SUBSTITUTED PYRIMIDINE RING COMPOUND, AND METHOD FOR ITS PRODUCTION CYP2B6, PFAS, CYP2F1 ALDH1A1 1430/4885SMN1; SMN2 4379/4885MAPT 4497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.